PSNL
- Personalis, Inc.
()
Overview
Company Summary
Personalis, Inc. is a company specializing in advanced genomics and data analytics. They operate in the field of precision medicine, which aims to tailor medical treatment to individual patients based on their unique genetic makeup.
Personalis provides comprehensive genomic sequencing and analysis services to biopharmaceutical and biotechnology companies, academic institutions, and research organizations. Their flagship product, ImmunoID NeXT Platform, combines whole exome sequencing, RNA sequencing, and tumor-normal matching to provide a comprehensive view of the tumor and immune response of patients with cancer.
Through their proprietary algorithms and bioinformatics capabilities, Personalis analyzes vast amounts of genomic data, extracting meaningful insights that can inform personalized treatments, therapeutic development, and clinical trials. Their platform helps to identify biomarkers, potential drug targets, and understand the immune response to cancer, enabling the development of more effective and targeted therapies.
Personalis also offers their ACE ImmunoID, a solution designed to support cell and gene therapy development by characterizing cells used in advanced therapy products and assessing the immune response towards specific antigens.
In summary, Personalis, Inc. leverages their expertise in genomics and data analytics to provide genomic sequencing and analysis services, primarily focused on cancer research and precision medicine. They assist pharmaceutical companies, research organizations, and academic institutions in developing targeted therapies and improving patient outcomes by understanding the individual genetic profiles of patients.